Dimensional Fund Advisors’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-29,769
| Closed | -$2.15M | – | 3284 |
|
|
2025
Q4 | $2.15M | Sell |
29,769
-355,716
| -92% | -$23M | ﹤0.01% | 2724 |
|
|
2025
Q3 | $16.8M | Buy |
385,485
+54,928
| +17% | +$2.22M | ﹤0.01% | 2081 |
|
|
2025
Q2 | $9.39M | Buy |
330,557
+180,477
| +120% | +$5.38M | ﹤0.01% | 2304 |
|
|
2025
Q1 | $4.44M | Sell |
150,080
-524,176
| -78% | -$16.3M | ﹤0.01% | 2529 |
|
|
2024
Q4 | $19.6M | Buy |
674,256
+2,139
| +0.3% | +$89.4K | ﹤0.01% | 2001 |
|
|
2024
Q3 | $30.9M | Sell |
672,117
-20,949
| -3% | -$909K | 0.01% | 1783 |
|
|
2024
Q2 | $28.3M | Sell |
693,066
-317,102
| -31% | -$9.1M | 0.01% | 1782 |
|
|
2024
Q1 | $25.8M | Sell |
1,010,168
-489,605
| -33% | -$7.67M | 0.01% | 1864 |
|
|
2023
Q4 | $13.6M | Sell |
1,499,773
-91,101
| -6% | -$609K | ﹤0.01% | 2181 |
|
|
2023
Q3 | $10.2M | Sell |
1,590,874
-314,499
| -17% | -$2.71M | ﹤0.01% | 2245 |
|
|
2023
Q2 | $21.1M | Buy |
1,905,373
+636,583
| +50% | +$7.98M | 0.01% | 1899 |
|
|
2023
Q1 | $19.5M | Buy |
1,268,790
+346,686
| +38% | +$7.63M | 0.01% | 1918 |
|
|
2022
Q4 | $20.5K | Buy |
922,104
+262,065
| +40% | +$3.91M | 0.01% | 1859 |
|
|
2022
Q3 | $10.8M | Buy |
660,039
+149,768
| +29% | +$2.87M | ﹤0.01% | 2125 |
|
|
2022
Q2 | $7.41M | Buy |
510,271
+137,519
| +37% | +$2.05M | ﹤0.01% | 2323 |
|
|
2022
Q1 | $6.88M | Buy |
372,752
+173,365
| +87% | +$2.95M | ﹤0.01% | 2437 |
|
|
2021
Q4 | $4.74M | Buy |
199,387
+112,084
| +128% | +$2.68M | ﹤0.01% | 2579 |
|
|
2021
Q3 | $2.15M | Buy |
+87,303
| New | +$1.9M | ﹤0.01% | 2835 |
|
Other funds holding RNAM
Dimensional Fund Advisors's RNAM Position: Q1 2026 in Review
Dimensional Fund Advisors sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 29,769 shares — an estimated $2.15M sold.
Dimensional Fund Advisors first reported a position in RNAM in Q3 2021 and held it in 18 quarters. The position peaked at $30.9M in Q3 2024. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Dimensional Fund Advisors reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Dimensional Fund Advisors sold 29,769 Avidity Biosciences shares in Q1 2026, an estimated $2.15M.
- Dimensional Fund Advisors first reported a position in Avidity Biosciences in Q3 2021 and held it in 18 quarters.
- Dimensional Fund Advisors's Avidity Biosciences position peaked at $30.9M in Q3 2024.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.